Is the LIFE-BTK Study Right For Me? | Abbott
CARDIOVASCULAR
hamburger

You May Be Eligible for the LIFE-BTK Study

If you have been diagnosed with critical limb ischemia, you may be eligible for the LIFE-BTK study if you:

  • Are 18 years of age or older
  • Have leg pain that occurs when resting
  • Have a foot wound
  • Have not had an amputation above the ankle
  • Have not had a stroke in the last 3 months
  • Are not currently on dialysis
  • Are not receiving or scheduled to receive treatment for cancer within 1 year before or after the clinical study
  • Are not pregnant and are on birth control if a female of childbearing potential
  • Have not tested positive for COVID‑19 in the last 2 months

Hear Dr. Parikh, LIFE-BTK Co-Principal Investigator, detail the importance of the LIFE-BTK study reflecting real patients.

CAUTION: Esprit™ BTK is an Investigational Device. Limited by Federal (USA) law for investigational use only.

Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.

Information contained herein for DISTRIBUTION to LIFE-BTK clinical trial sites ONLY.

Abbott
3200 Lakeside Dr., Santa Clara, CA 95054 USA. Tel: 1.800.227.9902

™ Indicates a trademark of the Abbott Group of Companies.

©2022 Abbott. All rights reserved. CL1015408

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.